Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ECOR vs ATHE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECOR Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–3 Matrix Metrics)

ECOR Overall Winner 6-Pillar Tally: ECOR 3 – 1 ATHE (2 Tie) Matrix Metrics: ECOR 5 – 3 ATHE

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Alterity Therapeutics Limited (ATHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas ATHE carries 39.2/100 (SELL) at $1.66 (N/M Forward P/E, -695.1% operating margin).

  • Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile ATHE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECOR vs ATHE
ECOR NASDAQ Head-to-Head Winner
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67
ATHE NASDAQ
Alterity Therapeutics Limited American Depositary Shares
Pharmaceutical Preparations
$1.66
-2.65% 1D
Market Cap $32.5M
TTM Revenue $3.6M
Forward P/E N/M
Beta / 30D Vol 1.05β · 102% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.5%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $2.14 · SMA50: $2.83

6-Pillar Scorecard Institutional Category Breakdown (ECOR 3 – 1 ATHE)

Columns: Metric · ECOR · ATHE
1. Valuation Multiples ECOR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x 9.0x
2. Growth & Scale ECOR
Revenue Growth (YoY) +11.5% -79.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $38M $3.6M
Market Cap $47.7M $32.5M
3. Profitability & Quality ATHE
Gross Margin 87.7% 92.7%
Operating Margin -33.1% -695.1%
Net Profit Margin -33.5% 0.0%
Return on Equity (ROE) -478.7% -55.0%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$6.9M -$25M EBITDA
Cash Flow Margin -18.1% N/A
Net Cash / Leverage $4.6M Net Debt $1.65 Book/Sh · -55.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECOR (5) vs ATHE (3)
Institutional Metric ECOR ATHE Criterion Row Edge
Market Capitalization
Scale
$47.7M $32.5M Larger Scale ECOR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+11.5% -79.0% Higher Growth ECOR
Operating Margin (TTM)
Profitability
-33.1% -695.1% Higher Margin ECOR
Net Profit Margin
Profitability
-33.5% 0.0% Higher Margin ATHE
Return on Equity (ROE)
Capital Efficiency
-478.7% -55.0% Higher ROE ATHE
52-Week Range Position
Momentum
6% ($4–$13) 3% ($2–$6) Stronger Trend ECOR
Beta / 30D Volatility
Risk Regime
1.52β · 155% Vol 1.05β · 102% Vol Lower Realized Risk ATHE
Unified Institutional Score
Composite Signal
56.8 / 100 (HOLD) 39.2 / 100 (SELL) Higher Composite ECOR
Trailing 12M Revenue (USD)
Operating Scale
$38M $3.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 92.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · 9.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.9M ($4.6M Net Debt) -$25M EBITDA ($1.65 Book/Sh · -55.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATHE +3.26 pp
ECOR: -34.01% · ATHE: -30.75%
3M Horizon ECOR +10.66 pp
ECOR: -53.9% · ATHE: -64.56%
6M Horizon ECOR +41.38 pp
ECOR: -19.03% · ATHE: -60.41%
1Y Horizon ECOR +50.07 pp
ECOR: -3.96% · ATHE: -54.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ECOR vs ATHE. Trailing 12-month operating profitability (ECOR -33.1% vs ATHE -695.1%) and valuation multiples (ECOR N/M vs ATHE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ECOR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$38M
Gross Margin87.7%
Op. Margin-33.1%
ROE / Fwd P/E-478.7% · N/M
ATHE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.6M
Gross Margin92.7%
Op. Margin-695.1%
ROE / Fwd P/E-55.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATHE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATHE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATHE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $32.5M market capitalization and -695.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ECOR vs ATHE Key Questions & Quantitative Answers

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Alterity Therapeutics Limited (ATHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas ATHE carries 39.2/100 (SELL) at $1.66 (N/M Forward P/E, -695.1% operating margin). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile ATHE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECOR leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with ATHE at -79.0% YoY revenue growth and +0.0% YoY earnings growth on $3.6M TTM revenue (92.7% gross margin, -695.1% operating margin). On trailing 12-month operating scale, ECOR generates $38M in USD-normalized revenue versus $3.6M for ATHE. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATHE.

ECOR screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas ATHE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.0x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus ATHE (-55.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, ATHE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.